Cargando…

Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1

Detalles Bibliográficos
Autores principales:	Ruan, Qiao-ling, Wang, Zhi-chao, Wei, Cheng-jiang, Wang, Wei, Yang, Qing-luan, Wu, Jing, Wan, Yan-min, Ge, Ling-ling, Zhang, Wen-hong, Li, Qing-feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236388/ https://www.ncbi.nlm.nih.gov/pubmed/37268605 http://dx.doi.org/10.1038/s41392-023-01498-1

Ejemplares similares

Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients
por: Zhang, Haiying, et al.
Publicado: (2022)

A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2
por: Zhang, Li, et al.
Publicado: (2021)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination
por: Huang, Wan-Ting, et al.
Publicado: (2022)

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
por: Niu, Ling, et al.
Publicado: (2021)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
por: Guo, Huimin, et al.
Publicado: (2022)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
por: Chi, Xiangyang, et al.
Publicado: (2022)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage Development
por: Ge, Ling-Ling, et al.
Publicado: (2022)

Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
por: Zhu, Liguo, et al.
Publicado: (2023)

Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels
por: LIU, Ren-qiang, et al.
Publicado: (2017)

Neutralizing and enhancing antibodies against SARS-CoV-2
por: Liu, Yafei, et al.
Publicado: (2022)

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination
por: Duan, Li-Jun, et al.
Publicado: (2022)

Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination
por: Chen, Xinhua, et al.
Publicado: (2021)

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
por: Gyang, Tirisham V., et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2
por: Wang, Shixia, et al.
Publicado: (2022)

Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
por: Wang, Shuang, et al.
Publicado: (2020)

Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion
por: Li, Chia-Jung, et al.
Publicado: (2022)

Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variants
por: Liu, Jinbiao, et al.
Publicado: (2021)

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
por: Chen, Xinhua, et al.
Publicado: (2022)

Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice
por: Lu, Ruei-Min, et al.
Publicado: (2023)

Down‐regulation of SARS‐CoV‐2 neutralizing antibodies in vaccinated smokers
por: Zhang, Jiahui, et al.
Publicado: (2022)

Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2021)

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants
por: Qu, Yuanyuan, et al.
Publicado: (2021)

Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
por: Wang, Qiao, et al.
Publicado: (2022)

Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection
por: Gao, Bo, et al.
Publicado: (2023)

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
por: Lyke, Kirsten E., et al.
Publicado: (2022)

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice
por: Song, Shuo, et al.
Publicado: (2022)

A human SARS-CoV neutralizing antibody against epitope on S2 protein
por: Duan, Jinzhu, et al.
Publicado: (2005)

Perspectives on the development of neutralizing antibodies against SARS-CoV-2
por: Ho, Mitchell
Publicado: (2020)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

SARS-CoV-2 re-infection, vaccination and neutralizing antibodies
por: Bongiovanni, Marco, et al.
Publicado: (2022)

Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2
por: Chen, Chunxia, et al.
Publicado: (2023)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
por: Srivastava, Vikram, et al.
Publicado: (2021)

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens
por: Jiang, Hu-Dachuan, et al.
Publicado: (2022)

A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern
por: Lee, I-Jung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pk3232r1t435rs4ntk0i9e05ir